Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 1/2017

Open Access 01-03-2017 | Review

Systemic Treatment of Adult Atopic Dermatitis: A Review

Authors: Matteo Megna, Maddalena Napolitano, Cataldo Patruno, Alessia Villani, Anna Balato, Giuseppe Monfrecola, Fabio Ayala, Nicola Balato

Published in: Dermatology and Therapy | Issue 1/2017

Login to get access

Abstract

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Due to its chronic nature and frequently occurring relapses, AD has a substantial effect on patients' quality of life, often requiring long-term systemic treatment, especially in adult patients, who are more frequently refractory to adequate topical treatment with mid- to high-potent corticosteroids and/or calcineurin inhibitors. Therefore, treatment with systemic therapies is often needed to take control of the disease, prevent exacerbations and improve quality of life. However, data regarding systemic treatment effectiveness and long-term safety in adult patients with AD are insufficient. Indeed, standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries. This review focuses on the use of systemic treatments in adult AD patients analyzing published literature.
Literature
1.
Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. J Eur Acad Dermatol Venereol. 2015;29:1905–12.PubMedCrossRef
2.
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132:1132–8.PubMedCrossRef
3.
Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68:498–506.PubMedCrossRef
4.
Napolitano M, Megna M, Patruno C, Gisondi P, Ayala F, Balato N. Adult atopic dermatitis: a review. G Ital Dermatol Venereol. 2016;151:403–11.PubMed
5.
6.
Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25:12–8.PubMedCrossRef
7.
Illi S, von Mutius E, Lau S, et al. Multicenter Allergy Study Group. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113:925–31.PubMedCrossRef
8.
Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol. 1998;139:834–9.PubMedCrossRef
9.
Wüthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol. 1999;83:464–70.PubMedCrossRef
10.
Schmitt J, Schmitt NM, Kirch W, Meurer M. Outpatient care and medical treatment of children and adults with atopic eczema. J Dtsch DermatGes. 2009;7:345–51.
11.
Su VY, Chen TJ, Yeh CM, et al. Atopic dermatitis and risk of ischemic stroke: a nationwide population-based study. Ann Med. 2014;46:84–9.PubMedCrossRef
12.
Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy. 2015;70:1300–8.PubMedCrossRef
13.
Silverberg JI, Silverberg NB, Lee-Wong M. Association between atopic dermatitis and obesity in adulthood. Br J Dermatol. 2012;166:498–504.PubMedCrossRef
14.
Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol. 2015;72:606–16.PubMedCrossRef
15.
Balato N, Patrì A, Napolitano M, Megna M, Patruno C. What’s new about atopic dermatitis and sporting activity. G Ital Dermatol Venereol. 2016;151:219–20.PubMed
16.
Werfel T, Schwerk N, Hansen G, Kapp A. The diagnosis and graded therapy of atopic dermatitis. Dtsch Arztebl Int. 2014;111:509–20.PubMedPubMedCentral
17.
Simon D. Systemic therapy of atopic dermatitis in children and adults. Curr Probl Dermatol. 2011;41:156–64.PubMedCrossRef
18.
Védie AL, Ezzedine K, Amazan E, et al. Long-term use of systemic treatments for moderate-to-severe atopic dermatitis in adults: a monocentric retrospective study. Acta Derm Venereol. 2016;96:802–6.PubMed
19.
Deleuran MS, Vestergaard C. Therapy of severe atopic dermatitis in adults. J Dtsch Dermatol Ges. 2012;10:399–406.
20.
Saeki H, Furue M, Furukawa F, et al. Committee for guidelines for the management of atopic dermatitis of Japanese dermatological association. Guidelines for management of atopic dermatitis. J Dermatol. 2009;36:563–77.PubMedCrossRef
21.
Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133:429–38.PubMedCrossRef
22.
Werner-Busse A, Kostev K, Heine G, Worm M. Impact of comorbidities on the treatment of atopic dermatitis in clinical practice. Int J Clin Pharmacol Ther. 2014;52:726–31.PubMedCrossRef
23.
24.
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26:1176–93.PubMedCrossRef
25.
26.
Kamata Y, Tominaga M, Takamori K. Itch in atopic dermatitis management. Curr Probl Dermatol. 2016;50:86–93.PubMedCrossRef
27.
Chan IH, Murrell DF. Itch management: physical approaches (UV phototherapy, acupuncture). Curr Probl Dermatol. 2016;50:54–63.PubMedCrossRef
28.
El Samahy MH, Attia EA, Saad AA, Mahmoud EY. Circulating CD4(+) CD25(high) FoxP3(+) T-regulatory cells in patients with atopic dermatitis after narrowband-ultraviolet B phototherapy. Int J Dermatol. 2015;54:424–9.CrossRef
29.
Holme SA, Anstey AV. Phototherapy and PUVA photochemotherapy in children. Photodermatol Photoimmunol Photomed. 2004;20:69–75.PubMedCrossRef
30.
Dogra S, Mahajan R; Indian Association of Dermatologists, Venereologists and Leprologists. Phototherapy for atopic dermatitis. Indian J Dermatol Venereol Leprol. 2015;81:10–5.
31.
Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170:501–13.PubMedCrossRef
32.
Kowalzick L, Kleinheinz A, Weichenthal M, Neuber K, Köhler I, Grosch J, Lungwitz G, Seegeberg C, Ring J. Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol. 1995;75:43–5.PubMed
33.
Tzaneva S, Seeber A, Schwaiger M, Hönigsmann H, Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001;45:503–7.PubMedCrossRef
34.
George SA, Bilsland DJ, Johnson BE, Ferguson J. Narrow-band (TL-01) UVBair-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol. 1993;128:49–56.PubMedCrossRef
35.
Rodenbeck DL, Silverberg JI, Silverberg NB. Phototherapy for atopic dermatitis. Clin Dermatol. 2016;34:607–13.PubMedCrossRef
36.
Bogaczewicz J, Malinowska K, Sysa-Jedrzejowska A, Wozniacka A. Medium dose ultraviolet al phototherapy and mRNA expression of interleukin 8, interferon γ, and chemokine receptor 4 in acute skin lesions in atopic dermatitis. Postepy Dermatol Alergol. 2016;33:170–5.PubMedPubMedCentralCrossRef
37.
Attili SK, Dawe RS, Ibbotson SH. Ultraviolet A1 phototherapy: One center’s experience. Indian J Dermatol Venereol Leprol. 2016.
38.
Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sönnichsen N, Czech W, Kapp A, Stege H, Grewe M, Schöpf E. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol. 1998;38:589–93.PubMedCrossRef
39.
Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schöpf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol. 1992;26:225–30.PubMedCrossRef
40.
Abeck D, Schmidt T, Fesq H, Strom K, Mempel M, Brockow K, Ring J. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol. 2000;42:254–7.PubMedCrossRef
41.
42.
Fernández-Guarino M, Aboin-Gonzalez S, Barchino L, Velazquez D, Arsuaga C, Lázaro P. Treatment of moderate and severe adult chronic atopic dermatitis with narrow-band UVB and the combination of narrow-band UVB/UVA phototherapy. Dermatol Ther. 2016;29:19–23.PubMedCrossRef
43.
Gambichler T, Othlinghaus N, Tomi NS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol. 2009;160:652–65.PubMedCrossRef
44.
Majoie IM, Oldhoff JM, van Weelden H, Laaper-Ertmann M, Bousema MT, Sigurdsson V, Knol EF, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Narrowband ultraviolet B and medium-dose ultraviolet al are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2009;60:77–84.PubMedCrossRef
45.
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045–60.PubMedCrossRef
46.
Tzaneva S, Kittler H, Holzer G, Reljic D, Weber M, Hönigsmann H, Tanew A. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol. 2010;162:655–60.PubMedCrossRef
47.
Uetsu N, Horio T. Treatment of persistent severe atopic dermatitis in 113Japanese patients with oral psoralen photo-chemotherapy. J Dermatol. 2003;30:450–7.PubMedCrossRef
48.
Der-Petrossian M, Seeber A, Hönigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol. 2000;142:39–43.PubMedCrossRef
49.
de Kort WJ, van Weelden H. Bath psoralen-ultraviolet A therapy in atopic eczema. J Eur Acad Dermatol Venereol. 2000;14:172–4.PubMedCrossRef
50.
51.
Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71:1218–33.PubMedPubMedCentralCrossRef
52.
Werfel T, Aberer W, Augustin M, et al. Neurodermitis: s2-guidelines. J Dtsch Dermatol Ges. 2009;7:1–46.
53.
Schmitt J, Schäkel K, Fölster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162:661–8.
54.
Garnacho-Saucedo G, Salido-Vallejo R, Moreno-Giménez JC. Atopic dermatitis: update and proposed management algorithm. Actas Dermosifiliogr. 2013;104:4–16.PubMedCrossRef
55.
Forte WC, Sumita JM, Rodrigues AG, Liuson D, Tanaka E. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunopathol (Madr). 2005;33:307–11.CrossRef
56.
Hello M, Aubert H, Bernier C, Néel A, Barbarot S. Atopic dermatitis of the adult. Rev Med Interne. 2016;37:91–9.
57.
Kim JE, Kim HJ, Lew BL, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (Part II): systemic treatment. Ann Dermatol. 2015;27:578–92.PubMedPubMedCentralCrossRef
58.
Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011;64:1074–84.PubMedCrossRef
59.
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema—a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606–19.PubMed
60.
Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T cell lymphoma developing in a patient on cyclosporine therapy. J Am Acad Dermatol. 2002;47:S165–7.PubMedCrossRef
61.
Sinha A, Velangi S, Natarajan S. Non-Hodgkin’s lymphoma following treatment of atopic eczema with cyclosporine A. Acta Derm Venereol. 2004;84:327–8.PubMedCrossRef
62.
Laube S, Stephens M, Smith AG, Whittaker SJ, Tan BB. Lymphomatoid papulosis in a patient with atopic eczema on long-term cyclosporine therapy. Br J Dermatol. 2005;152:1346–8.PubMedCrossRef
63.
Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338:137–40.PubMedCrossRef
64.
Ohtsuka T. Different effect of oral cyclosporine therapy and oral antihistamine therapy on serum high-sensitivity C-reactive protein level and thymus and activation-regulated chemokine level in atopic dermatitis in older children and adulthood. Int J Dermatol. 2015;54:648–55.PubMedCrossRef
65.
Kim JE, Shin JM, Ko JY, Ro YS. Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine. Dermatol Ther. 2016;29:120–5.PubMedCrossRef
66.
van der Schaft J, Politiek K, van den Reek JM, et al. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol. 2015;172:1621–7.PubMedCrossRef
67.
Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002;147:324–30.
68.
Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomized controlled trial. Lancet. 2006;367:839–46.PubMedCrossRef
69.
Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147:474–88.PubMedCrossRef
70.
Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol. 2002;43:125–7.PubMedCrossRef
71.
Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol. 2008;33:710–1.PubMedCrossRef
72.
Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema using thiopurine methlytransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147:308–15.PubMedCrossRef
73.
Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat. 2009;20:141–5.PubMedCrossRef
74.
Thomsen SF, Karlsmark T, Kk Clemmensen, et al. Outcome of treatment with azathioprine in severe atopic dermatitis: a 5-year retrospective study of adult outpatients. Br J Dermatol. 2015;172:1122–4.PubMedCrossRef
75.
Schram ME, Roekevisch E, Leeflang MMG, Boos JD, Schmitt J. SpulsPI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353–9.PubMedCrossRef
76.
Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156:346–51.PubMedCrossRef
77.
Goujon C, Bérard F, Dahel K, et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol. 2006;16:155–8.PubMed
78.
Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010;24:43–9.PubMedCrossRef
79.
Politiek K, van der Schaft J, Coenraads PJ, de Bruin-Weller MS, Schuttelaar ML. Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis. Br J Dermatol. 2016;174:201–3.PubMedCrossRef
80.
Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001;137:870–3.PubMed
81.
Ballester I, Silvestre JF, Pérez-Crespo M, Lucas A. Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients. Actas Dermosifiliogr. 2009;100:883–7.PubMedCrossRef
82.
Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30:729–47.PubMedCrossRef
83.
Sollinger HW. Enteric coated mycophenolate sodium- current and future use in transplant patients. Expert Rev Clin Immunol. 2005;1:203–11.PubMedCrossRef
84.
van Velsen SG, Haeck IM, Bruijnzell-Koomen CA, de Bruin-Weller MS. First experience with enteric-coated mycophenolate sodium (Myfortic) in severe recalcitrant adult atopic dermatitis: an open label study. Br J Dermatol. 2009;160:687–91.PubMedCrossRef
85.
Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol. 2001;144:638–9.PubMedCrossRef
86.
Thijs JL, Van Der Geest BA, Van Der Schaft J, et al. Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis. J Dermatolog Treat. 2016;13:1–4.CrossRef
87.
Balal M, Demir E, Paydas S, et al. Uncommon side effect of MMF in renal transplant recipients. Ren Fail. 2005;27:591–4.PubMedCrossRef
88.
Nguyen RH, Cruz PD Jr. Hepatitis due to mycophenolate mofetil used to treat atopic dermatitis and allergic contact dermatitis. Dermatitis. 2014;25:284–5.PubMedPubMedCentralCrossRef
89.
Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808–17.PubMedCrossRef
90.
Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A. Treatment of atopic eczema with oral alitretinoin. Br J Dermatol. 2010;162:217–8.PubMedCrossRef
91.
D’Erme AM, Milanesi N, Agnoletti AF, Maio V, Massi D, Gola M. Efficacy of treatment with oral alitretinoin in patient suffering from lichen simplex chronicus and severe atopic dermatitis of hands. Dermatol Ther. 2014;27:21–3.PubMedCrossRef
92.
93.
Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121:122.PubMedCrossRef
94.
Sedivá A, Kayserová J, Vernerová E, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol. 2008;121:1515–6.PubMedCrossRef
95.
Sanchez-Ramon S, Equiluz-Garcia I, Rodriquez-Mazariego ME, et al. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol. 2013;23:190–6.PubMed
96.
Mc Donald BS, Jones J, Rustin M. Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients. Clin Exp Dermatol. 2016;41:45–7.CrossRef
97.
Nograles KE, Zaba LC, Shemer A. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123:1244–52.PubMedPubMedCentralCrossRef
98.
Puya R, Alvarez-López M, Velez A, Casas Asuncion E, Moreno JC. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51:115–6.PubMedCrossRef
99.
100.
Fernández-Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C, Suárez Fernández R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105:312–3.PubMedCrossRef
101.
Weiss D, Schaschinger M, Ristl R, Gruber R, Kopp T, Stingl G, Bangert C. Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2/22 expression. J Am Acad Dermatol. 2016;74:945–73.PubMedCrossRef
102.
Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severeatopic dermatitis. Exp Dermatol. 2016. doi:10.​1111/​exd.​13112 [Epub ahead of print].PubMed
103.
Samorano LP, Hanifin JM, Simpson EL, Leshem YA. Inadequate response to ustekinumab in atopic dermatitis—a report of two patients. J Eur Acad Dermatol Venereol. 2016;30:522–3.PubMedCrossRef
104.
Lis-Święty A, Skrzypek-Salamon A, Arasiewicz H, Brzezińska-Wcisło L. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy. Allergol Int. 2015;64:382–3.PubMedCrossRef
105.
106.
Johansson SGO, Oman H, Nopp A, Pettersson S. The importance of IgE antibody levels in anti-IgE treatment. Allergy. 2006;61:1216–9.PubMedCrossRef
107.
Di Lucca-Chrisment J. Dermatological implications of omalizumab, an anti-IgE antibody. Rev Med Suisse. 2015;11(779–80):782–3.
108.
Andres C, Belloni B, Mempel M, Ring J. Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep. 2008;8:179–80.PubMedCrossRef
109.
Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohé C. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res. 2011;16:407–10.PubMedPubMedCentralCrossRef
110.
Romano C, Sellitto A, De Fanis U, et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investig. 2015;35:159–68.PubMedCrossRef
111.
Thaiwat S, Sangasapaviliya A. Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol. 2011;29:357–60.PubMed
112.
113.
114.
Amrol D. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. South Med J. 2010;103:554–8.PubMedCrossRef
115.
Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F, Paravisini A, Sánchez-Ramón S, Suárez Fernández R. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012;103:624–8.PubMedCrossRef
116.
Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor. FcepsilonRI. Cutis. 2007;80:38–40.PubMed
117.
Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120:1223–5.PubMedCrossRef
118.
Holm JG, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18–26.PubMedCrossRef
119.
Quist SR, Ambach A, Göppner D, et al. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E. Acta Derm Venereol. 2013;93:206–8.PubMedCrossRef
120.
Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55(1):168–70.PubMedCrossRef
121.
Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis. 2008;69:78–80.PubMed
122.
Lee E, Sheinkopf LE, Asif W, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55:168–70.CrossRef
123.
Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38:496–500.PubMedCrossRef
124.
Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530–7.PubMedCrossRef
125.
Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab. Acta Derm Venereol. 2016;96:72–6.PubMedCrossRef
126.
Toledo F, Silvestre JF, Muñoz C. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol. 2012;26:1325–7.PubMedCrossRef
127.
Hotze M, Baurecht H, Rodríguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 2014;69:132–5.PubMedCrossRef
128.
Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course—a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990.PubMed
129.
Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53:338–40.PubMedCrossRef
130.
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9.PubMedCrossRef
131.
Eichenfield LF, Friedlander SF, Simpson EL, Irvine AD. Assessing the new and emerging treatments for atopic dermatitis. Semin Cutan Med Surg. 2016;35:S92–6.CrossRef
132.
Tsianakas A, Ständer S. Dupilumab: a milestone in the treatment of atopic dermatitis. Lancet. 2016;387:4–5.PubMedCrossRef
133.
Lauffer F, Ring J. Target-oriented therapy: Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2016;21:81–9.PubMedCrossRef
134.
Tsianakas A, Luger TA. The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis. Expert Opin Biol Ther. 2015;15:1657–60.PubMedCrossRef
135.
Tavakolpour S. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus. Dermatol Ther. 2016;29:299.PubMedCrossRef
136.
Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293–300.PubMedCrossRef
137.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375:2335–48.PubMedCrossRef
138.
Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;2(387):40–52.CrossRef
139.
Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491–8.PubMedCrossRef
140.
Simpson EL, Godkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75:506–15.PubMedCrossRef
141.
Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7:1043–58.PubMedCrossRef
142.
D’Erme AM. The beginning of biological treatment era in the atopic dermatitis management. Dermatol Ther. 2016;29:208–9.PubMedCrossRef
143.
Blakely K, Gooderham M, Papp K. Dupilumab, A monoclonal antibody for atopic dermatitis: a review of current literature. Skin Therapy Lett. 2016;21:1–5.PubMed
144.
Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. (Review.). 2007;8:364–72.
145.
Philip J. Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther. 2014;1:1–20.
146.
Fala L. Otezla (Apremilast), an Oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105–10.
147.
Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148:890–7.PubMedPubMedCentralCrossRef
148.
Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11:341–6.PubMed
Metadata
Title
Systemic Treatment of Adult Atopic Dermatitis: A Review
Authors
Matteo Megna
Maddalena Napolitano
Cataldo Patruno
Alessia Villani
Anna Balato
Giuseppe Monfrecola
Fabio Ayala
Nicola Balato
Publication date
01-03-2017
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2017
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-016-0170-1

Other articles of this Issue 1/2017

Dermatology and Therapy 1/2017 Go to the issue

Review

Skin Manifestations of Insulin Resistance: From a Biochemical Stance to a Clinical Diagnosis and Management

Review

Metal Hypersensitivity Reactions to Orthopedic Implants

Case Report

A Slowly Growing Orange Patch on the Cheek: Diagnosis of Lupus Vulgaris 20 Years After Onset of First Skin Changes

Review

Vegas (Verruciform Genital-Associated) Xanthoma: A Comprehensive Literature Review

Review

Current and Emerging Medical Therapies for Primary Hyperhidrosis

Original Research

Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits